SYNT-113

SYNT-113 is an oral small molecule therapeutic currently in preclinical development by Syntis Bio for the treatment of obesity. The program is built upon a "derisked molecule and target," suggesting the application of Syntis Bio's proprietary delivery technologies to a validated pharmacological pathway or an existing compound to enhance its therapeutic index. Syntis Bio's broader approach focuses on gut-restricted therapies that mimic the physiological effects of metabolic surgery, such as duodenal exclusion, to treat metabolic conditions like obesity and type 2 diabetes. As a preclinical asset, SYNT-113 represents the company's effort to expand its metabolic pipeline beyond its lead duodenal-coating candidate, SYNT-101.